{'fraction_non_alphanumeric': 0.04205607476635514, 'fraction_numerical': 0.010903426791277258, 'mean_word_length': 5.768421052631579, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Growth hormone—Insulin‐like growth factor 1 axis hyperactivity on bone fibrous dysplasia in McCune‐Albright Syndrome

In fibrous dysplasia (BFD), normal bone and bone marrow are replaced by fibro‐osseous tissue, leading to fracture, deformity and pain. BFD may be isolated, or in association with cutaneous hyperpigmentation and/or hyperfunctioning endocrinopathies, termed McCune‐Albright syndrome (MAS). GH hypersecretion has been described in 10%‐20% of MAS‐BFD patients. Aim of the study was to determine the impact of GH‐insulin like growth factor 1 (IGF1) axis hyperactivity on MAS‐BFD morbidities and the efficacy of GH excess therapy.